Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
FDA-approved: Replacement of extracellular fluid losses in patients who require fluid resuscitation or maintenance, particularly in metabolic acidosis or mild to moderate acid-base disturbances.,Off-label: Not commonly used off-label; may be used in specific electrolyte imbalances or perioperative settings where balanced crystalloid is preferred.
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Not applicable (components are endogenous substances; half-life reflects renal clearance and volume status, typically 2-4 hours for sodium and chloride in euvolemic patients).
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Acetate and gluconate are metabolized primarily in the liver and peripheral tissues to bicarbonate ions. Electrolytes are excreted or reabsorbed via renal mechanisms.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Renal: 100% (electrolytes and buffer components are excreted unchanged by the kidneys; no biliary or fecal elimination).
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
0% (electrolytes and buffer components are not protein-bound; free in plasma).
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Sodium: 0.15-0.3 L/kg (extracellular fluid space); Chloride: similar; Bicarbonate precursor (acetate/gluconate): distributed in total body water (~0.6 L/kg).
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Intravenous: 100% (directly administered into bloodstream); not applicable to other routes.
Intravenous: 100% bioavailability.
No specific dosage adjustment; use with caution in severe renal impairment due to risk of electrolyte imbalances and fluid overload.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
No specific dosage adjustment; monitor for electrolyte disturbances and fluid overload.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Weight-based: 100-150 m L/kg/24 hours for maintenance; adjust based on clinical condition and electrolyte requirements.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Use with caution due to increased risk of fluid overload and electrolyte imbalances; start at lower end of dosing range and monitor closely.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
No FDA black box warning.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Use with caution in patients with congestive heart failure, severe renal impairment, hyponatremia, hyperkalemia, hypermagnesemia, or conditions predisposing to fluid overload.,May cause fluid and/or solute overload, pulmonary edema, or electrolyte disturbances.,Monitor serum electrolytes, fluid balance, and acid-base status during prolonged therapy.
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hypersensitivity to any component.,Severe hyperkalemia or severe hypernatremia.,Patients with significant fluid overload or severe metabolic alkalosis.,Concurrent use with products containing calcium (risk of precipitation in IV line, though not directly contraindicated with this product, but caution).
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No known food interactions. However, oral intake may be restricted or modified based on underlying condition (e.g., bowel rest, NPO status).
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
Isolyte S p H 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid and electrolyte replacement.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Isolyte S p H 7.4 constituents are normal components of body fluids and breast milk. No specific M/P ratio is available; however, there is no expected risk to the nursing infant when the solution is used as indicated.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
Pregnancy may alter fluid and electrolyte requirements due to increased plasma volume and glomerular filtration rate. Dosing should be individualized based on maternal status; no fixed dose adjustment is necessary, but careful monitoring of volume status is recommended.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
ISOLYTE S p H 7.4 is a balanced isotonic crystalloid solution containing multiple electrolytes (sodium, potassium, magnesium, calcium, acetate, gluconate) and is buffered to p H 7.4. It is indicated for use as a replacement fluid in extracellular volume depletion (e.g., dehydration, burns, surgery) and for maintenance fluid therapy. Avoid use in patients with hyperkalemia, hypercalcemia, or severe metabolic alkalosis. The acetate and gluconate act as bicarbonate precursors, making it suitable for correcting mild metabolic acidosis. In patients with renal impairment, monitor electrolytes closely due to risk of accumulation. Do not confuse with ISOLYTE S without p H adjustment (which may have different buffer composition).
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This solution is given intravenously to replace lost fluids and electrolytes.,Tell your healthcare provider if you have kidney disease, heart disease, or any electrolyte imbalances.,Report any signs of fluid overload, such as shortness of breath, swelling in ankles or feet, or rapid weight gain.,Do not drive or operate heavy machinery until you know how this medication affects you.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for blood tests to monitor electrolyte levels.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is classified as Category C. Isolyte S pH 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid an. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.